Aventis Pharma Limited

Rhone Poulenc Rorer

Aventis Pharmaceuticals Inc.

Peter Charles Astles

Neil Victor Harris

Andrew David Morley

Barry Porter

Paul Joseph Cox

Iain M McLay

Clive McCarthy

Christopher Smith

Stevan Wakefield Djuric

John R Regan

Frank Halley

Daniel Gerard McGarry

Julian Roy Levell

Gregory Bernard Poli

Roger J Walsh

Kevin Joseph Moriarty

Yong Gong

Rose Mappilakunnel Mathew

Shelley Bower

Heinz Pauls

Kent W Neuenschwander

David John Aldous

Christopher Hulme

Andrew Paul Van Sickle

Fu-Chih Huang

Paul R Eastwood

Andrew Bridge

Tahir Majid

Martyn Foster

Alan Roach

Mark Czekaj

Paul Robert Eastwood

Justine Yeun Quai Lai

David Edward Clark

Olivier Houille

Guyan Liang

James R Pribish

Alan John Collis

Richard Alan Lewis

Mark Francis Harper

Roger John Aitchison Walsh

Gregory Bernard Rhone-Poulenc Rorer Inc Poli

Fu-Chih Rhone-Poulenc Rorer Inc Huang

Daniel Gerard Rhone-Poulenc Rorer Inc Mcgarry

Stevan Wakefield Rhone-Poulenc Rorer Inc Djuric

Christopher Rhone-Poulenc Rorer Inc Hulme

John Robinson Rhone-Poulenc Rorer Inc Regan

Kevin Joseph Rhone-Poulenc Rorer Inc Moriarty

Rose M Rhone-Poulenc Rorer Inc Mathew

This invention relates to compounds of formula which inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.

1-aroyl-piperidinyl benzamidines

This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and pharmaceutically acceptable salts of the compounds of formula (I) and N-oxides thereof, Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmnaceutical compositions comprising compoundS of formula (I), their phatmaceUtical use and methods for their preparation.

Substituted azabicyclic compounds

Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.

Chemical compounds

Substituted anilides

Substituted &bgr;-alanines

Substituted phenyl compounds

This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H;

Substituted phenyl compounds with a substituent having a thienyl ring

Substituted phenyl compounds with a substituent having A

Growing community of inventors

Dagenham, United Kingdom

Peter Charles Astles